Pluripotent stem cell-derived organoid-based high throughput drug screening using single cell RNAseq as readout
* Provides info from a more physiologically relevant 3D human system than current approaches
* Provides access to cell types not readily available
* Multiple cell lines can be combined in one organoid, cutting down cost – “chimeric organoid” approach
* Analysis is agnostic to genes involved
* Analysis is not limited by antibody availability or off target interactions
* Does not require large initial equipment investment
* Work on calculation
* Differences in cell line growth can be identified by RNAseq
* Can be used in non-human systems
Co-founder
Dr. Yu-Chieh (Jack) Wang received his doctoral degree in medicinal chemistry from The Ohio State University and performed his postdoctoral training in The Scripps Research Institute. He is a senior investigator and experienced leader who strives to develop innovative solutions for challenges in stem cell technologies, human disease modeling, and regenerative medicine in academia and biotechnology industry. Bringing his 20 years of research experience across multiple disciplinaries, Jack co-founds OrganoidPro to better promote the advancement and application of human stem cells and organoid systems for answering fundamental biological questions and developing novel therapeutics.
Prior to founding OrganoidPro, Dr. Wang was an R&D Director for stem cell technologies and emerging platforms at Resilience US to improve company’s processes and analyses for large-scale production of human induced pluripotent stem cells (hiPSCs) and their differentiated derivatives compatible with the use of drug screening and cell therapy. Dr. Wang also has held faculty positions in three research-oriented academic institutes and led research programs as a principal investigator with active funding from government agencies and private organizations. His teams have established and leveraged cutting-edge approaches including hiPSCs, organoids, gene editing, and systems biology techniques to make novel discoveries and scientific contributions through studying cell biology, gene alterations, neurodevelopmental abnormalities, and anticancer targets relevant to the alterations of glycoenzymes.
Co-founder
IT/Engineering/
Odie brings vast engineering and technical know-how from 25 years in highly regulated industries including medical, life sciences, DoD and aerospace to make sure things go smoothly
Interested? Fill out the form and fill me in with the details :) Let's get to work!
Powered by w3.css